FLT3 and acute myeloid leukemia: In the treatment of AML, this has been best demonstrated by treatment of patients with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), an alteration present in about 30% of adult AML patients and 15% of pediatric AML patients.